65,437 trials
Asthma
Primary: Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period…
Ewing Sarcoma of Bone · Extraosseous Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor
Primary: The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. — 0 number of toxicities
Clinical Indication for a Head MRI
Primary: Number of Head Images Successfully Collected — 10 Images
Primary Insomnia
Primary: Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1 — 48.7; 22.4 minutes — p=<0.00001
Depression
Primary: Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16 — 18.3; 18.7; 19.8 units on a scale
Lung Cancer
Primary: Improvement in Cancer Detection as Measured by Localized Receiver Operating Characteristic) LROC Changes Under the LROC Curve. — 0.460; 0.558 unitless — p=0.05
Adult Attention Deficit Hyperactivity Disorder · Cocaine Dependence
Primary: Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use — 7; 18; 30 percentage of participants
Primary Insomnia
Primary: Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1 — 42.6; 23.1 minutes — p=<0.00001
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 8.08; 7.58; 0.03; -0.47 percent of HbA1c in blood — p=<0.001
Smoking Cessation
Primary: Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking — 32.1; 6.9 percentage of participants — p=<0.0001
Alcoholism · Cocaine Dependence
Primary: Percent of Participants Abstinent From Cocaine During Last 3 Weeks of 13 Week Trial — 17; 6 Percent of participants — p=0.01
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria — 10 percentage of participants
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.58; -0.68; -0.76; -0.91 percentage of HbA1c
Lymphocytic Leukemia · Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) — 61 percentage of participants
Incontinence · Enuresis
Primary: Change in the Mean Number of Accidents Across Children — -1.3 Accidents